Financial Ratios Virax Biolabs Group Limited
Equities
VRAX
KYG9495L1251
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2145 USD | +3.62% |
|
-5.80% | -37.97% |
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -1.29K | -2.45K | -72.67 | -49.9 | -64.68 | |
Return on Total Capital | 72.22 | 116.96 | -91.24 | -52.89 | -66.76 | |
Return On Equity % | 65.75 | 172.53 | -141.63 | -95.98 | -114.47 | |
Return on Common Equity | 76.28 | 210.28 | -133.9 | -92.92 | -109.58 | |
Margin Analysis | ||||||
Gross Profit Margin % | -7.62 | - | -15.94 | 32.34 | -838.21 | |
SG&A Margin | 415.83 | - | 62.31K | 2.94K | 68.39K | |
EBITDA Margin % | - | - | - | -3.87K | -93.29K | |
EBITA Margin % | -520.54 | - | -66.96K | -3.9K | -97.34K | |
EBIT Margin % | -520.54 | - | -66.96K | -3.9K | -97.34K | |
Income From Continuing Operations Margin % | -543.46 | - | -63.75K | -4.31K | -95.83K | |
Net Income Margin % | -525.75 | - | -63.75K | -4.3K | -95.74K | |
Net Avail. For Common Margin % | -525.75 | - | -63.75K | -4.3K | -95.74K | |
Normalized Net Income Margin | -321.95 | - | -39.84K | -2.45K | -61.15K | |
Levered Free Cash Flow Margin | -185.06 | - | -31.67K | -3.19K | -51.27K | |
Unlevered Free Cash Flow Margin | -170.61 | - | -31.55K | -3.18K | -50.7K | |
Asset Turnover | ||||||
Asset Turnover | 3.98 | - | 0 | 0.02 | 0 | |
Fixed Assets Turnover | - | - | - | 0.3 | 0 | |
Inventory Turnover (Average Inventory) | - | - | 0.44 | 0.64 | 0.32 | |
Short Term Liquidity | ||||||
Current Ratio | 0.05 | 0.04 | 10.61 | 25.94 | 7.27 | |
Quick Ratio | 0.02 | 0.02 | 10.35 | 23.01 | 6.47 | |
Operating Cash Flow to Current Liabilities | -0.47 | -0.65 | -4.6 | -37 | -6.78 | |
Days Outstanding Inventory (Average Inventory) | - | - | 828.22 | 570.18 | 1.15K | |
Average Days Payable Outstanding | - | - | 14.05K | 97.1 | 291.23 | |
Long Term Solvency | ||||||
Total Debt/Equity | -21.13 | - | 1.64 | 4.36 | 13.08 | |
Total Debt / Total Capital | -26.78 | - | 1.62 | 4.18 | 11.57 | |
LT Debt/Equity | - | - | - | 3.43 | 5.34 | |
Long-Term Debt / Total Capital | - | - | - | 3.29 | 4.72 | |
Total Liabilities / Total Assets | 2.2K | 2.56K | 9.26 | 6.29 | 15.01 | |
EBIT / Interest Expense | -22.5 | -112.3 | -370.62 | -227.18 | -105.93 | |
EBITDA / Interest Expense | - | - | - | -223.34 | -100.2 | |
(EBITDA - Capex) / Interest Expense | - | - | - | -258.78 | -110.58 | |
Total Debt / EBITDA | - | - | - | -0.04 | -0.12 | |
Net Debt / EBITDA | - | - | - | 0.57 | 0.62 | |
Total Debt / (EBITDA - Capex) | - | - | - | -0.03 | -0.11 | |
Net Debt / (EBITDA - Capex) | - | - | - | 0.49 | 0.56 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 23.97 | - | - | 1.73K | -95.95 | |
Gross Profit, 1 Yr. Growth % | -120.62 | - | - | -3.81K | -204.9 | |
EBITDA, 1 Yr. Growth % | - | - | - | - | -2.4 | |
EBITA, 1 Yr. Growth % | -1.03 | 168.98 | 230.67 | 6.51 | 0.93 | |
EBIT, 1 Yr. Growth % | -1.03 | 168.98 | 230.67 | 6.51 | 0.93 | |
Earnings From Cont. Operations, 1 Yr. Growth % | -9 | 160.04 | 211.9 | 23.48 | -9.97 | |
Net Income, 1 Yr. Growth % | -8.37 | 162.5 | 219.37 | 23.38 | -9.98 | |
Normalized Net Income, 1 Yr. Growth % | -7.97 | 164.05 | 224.03 | 6.78 | 0.86 | |
Diluted EPS Before Extra, 1 Yr. Growth % | -60.23 | -33.99 | 185.23 | -34.56 | -51.58 | |
Inventory, 1 Yr. Growth % | - | -0.57 | 15.01 | 1.17K | 2.36 | |
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | - | - | 41.71 | |
Total Assets, 1 Yr. Growth % | 75.24 | 22.93 | 20.05K | -44.11 | 17.19 | |
Tangible Book Value, 1 Yr. Growth % | -38.39 | 49.78 | -1.02K | -40.58 | 6.38 | |
Common Equity, 1 Yr. Growth % | -38.39 | 49.78 | -1.04K | -41.2 | 6.14 | |
Cash From Operations, 1 Yr. Growth % | 921.17 | 37.09 | 414.76 | 49.46 | -26.95 | |
Capital Expenditures, 1 Yr. Growth % | - | - | - | - | -36.6 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | 139.34 | 963.1 | 82.72 | -32.27 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | 155.06 | 1K | 82.75 | -32.79 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | - | -73.71 | - | -14 | |
Gross Profit, 2 Yr. CAGR % | - | - | -61.96 | - | 523.51 | |
EBITA, 2 Yr. CAGR % | - | 63.16 | 198.23 | 87.67 | 3.68 | |
EBIT, 2 Yr. CAGR % | - | 63.16 | 198.23 | 87.67 | 3.68 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 53.83 | 184.79 | 96.24 | 5.44 | |
Net Income, 2 Yr. CAGR % | - | 55.09 | 189.54 | 98.51 | 5.39 | |
Normalized Net Income, 2 Yr. CAGR % | - | 55.89 | 192.51 | 90.96 | 3.78 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | -48.77 | 37.72 | 37.01 | -43.74 | |
Inventory, 2 Yr. CAGR % | - | - | 6.93 | 281.95 | 179.88 | |
Total Assets, 2 Yr. CAGR % | - | 46.77 | 1.47K | 961.1 | -19.07 | |
Tangible Book Value, 2 Yr. CAGR % | - | -3.94 | 270.83 | 133.57 | -20.49 | |
Common Equity, 2 Yr. CAGR % | - | -3.94 | 274.51 | 134.66 | -21 | |
Cash From Operations, 2 Yr. CAGR % | - | 4.24 | 166.12 | 177.87 | 4.49 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 243.96 | 344.78 | 9.06 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 257.6 | 352.78 | 8.64 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | -55.91 | 8.1 | - | |
Gross Profit, 3 Yr. CAGR % | - | - | -68.98 | 75.03 | - | |
EBITA, 3 Yr. CAGR % | - | - | 106.48 | 111.6 | 52.62 | |
EBIT, 3 Yr. CAGR % | - | - | 106.48 | 111.6 | 52.62 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 94.7 | 115.55 | 51.35 | |
Net Income, 3 Yr. CAGR % | - | - | 97.31 | 117.88 | 52.51 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 98.95 | 112.75 | 54.36 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | -8.97 | 7.47 | -3.18 | |
Inventory, 3 Yr. CAGR % | - | - | - | 143.88 | 108.07 | |
Total Assets, 3 Yr. CAGR % | - | - | 657.12 | 417.28 | 409.1 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 103.86 | 101.42 | 79.71 | |
Common Equity, 3 Yr. CAGR % | - | - | 105.21 | 102.04 | 80.13 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 77.72 | 119.56 | 78.01 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 179.19 | 134.39 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 186.55 | 136.57 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | -42.4 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 3.01 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 56.75 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 56.75 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 52.34 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 53.53 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 54.97 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | -24.91 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 209.56 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 39.88 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 40.08 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 43.71 |
- Stock Market
- Equities
- VRAX Stock
- Financials Virax Biolabs Group Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















